DE60035270D1 - Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine - Google Patents

Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Info

Publication number
DE60035270D1
DE60035270D1 DE60035270T DE60035270T DE60035270D1 DE 60035270 D1 DE60035270 D1 DE 60035270D1 DE 60035270 T DE60035270 T DE 60035270T DE 60035270 T DE60035270 T DE 60035270T DE 60035270 D1 DE60035270 D1 DE 60035270D1
Authority
DE
Germany
Prior art keywords
sub
line
formulae
amino acid
modified form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60035270T
Other languages
English (en)
Inventor
Richard K Gordon
Deborah R Moorad
Bhupendra P Doctor
Gregory E Watler Garcia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Army Medical Research and Materiel Command USAMRMC
Original Assignee
US Army Medical Research and Materiel Command USAMRMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Army Medical Research and Materiel Command USAMRMC filed Critical US Army Medical Research and Materiel Command USAMRMC
Application granted granted Critical
Publication of DE60035270D1 publication Critical patent/DE60035270D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60035270T 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine Expired - Lifetime DE60035270D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13444699P 1999-05-17 1999-05-17
PCT/US2000/013215 WO2000069891A2 (en) 1999-05-17 2000-05-15 Previns as specific inhibitors and therapeutic agents for botulinum toxin b and tetanus neurotoxins

Publications (1)

Publication Number Publication Date
DE60035270D1 true DE60035270D1 (de) 2007-08-02

Family

ID=22463433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60035270T Expired - Lifetime DE60035270D1 (de) 1999-05-17 2000-05-15 Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine

Country Status (9)

Country Link
US (3) US6573244B1 (de)
EP (1) EP1179010B1 (de)
JP (1) JP2003501012A (de)
AT (1) ATE365173T1 (de)
AU (1) AU772985B2 (de)
CA (1) CA2372304A1 (de)
DE (1) DE60035270D1 (de)
IL (1) IL146459A0 (de)
WO (1) WO2000069891A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US6713444B1 (en) * 1999-05-14 2004-03-30 The United States Of America As Represented By The Secretary Of The Army Buforin I as a specific inhibitor and therapeutic agent for botulinum toxin B and tetanus neurotoxins
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
DE10038511A1 (de) * 2000-08-08 2002-02-21 Bhs Corr Masch & Anlagenbau Längs-Bearbeitungs-Maschine für Wellpappe-Bahnen
US7332567B2 (en) * 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
US7350590B2 (en) * 2002-11-05 2008-04-01 Weatherford/Lamb, Inc. Instrumentation for a downhole deployment valve
US7700738B2 (en) 2005-01-27 2010-04-20 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US8658372B2 (en) * 2005-06-10 2014-02-25 The United States Of America, As Represented By The Secretary Of The Navy Affinity-based detection of biological targets
US20070154448A1 (en) 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
CA2680741A1 (en) 2007-03-22 2009-01-15 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
AU2017326253B2 (en) 2016-09-13 2021-10-21 Allergan, Inc. Stabilized non-protein clostridial toxin compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4059693A (en) * 1976-06-11 1977-11-22 University Patents, Inc. Analgesic action of substance P
US5137873A (en) * 1990-07-27 1992-08-11 The Children's Medical Center Corporation Substance p and tachykinin agonists for treatment of alzheimer's disease
EP0593615B1 (de) * 1991-07-10 1996-01-31 MERCK SHARP & DOHME LTD. Aromatische verbindungen diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
WO1993001159A1 (en) * 1991-07-10 1993-01-21 Merck Sharp & Dohme Limited Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
CA2260269A1 (en) * 1996-07-17 1998-01-22 Merck & Co., Inc. Alteration of circadian rhythmicity with a tachykinin antagonist
US5945508A (en) * 1996-07-23 1999-08-31 Witten; Mark L. Substance P treatment for immunostimulation
KR100263583B1 (ko) * 1997-05-28 2000-08-01 박종헌 항균 펩타이드의 대량 제조방법 및 그에 유용한 플라즈미드 벡타
KR100314721B1 (ko) * 1998-01-22 2001-11-23 김일웅 생물학적 활성이 있는 신규한 펩타이드
US6573244B1 (en) * 1999-05-17 2003-06-03 The United States Of America As Represented By The Secretary Of The Army Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins

Also Published As

Publication number Publication date
WO2000069891A2 (en) 2000-11-23
AU772985B2 (en) 2004-05-13
CA2372304A1 (en) 2000-11-23
US20060247176A1 (en) 2006-11-02
EP1179010B1 (de) 2007-06-20
US7375079B2 (en) 2008-05-20
US20050113304A1 (en) 2005-05-26
US6573244B1 (en) 2003-06-03
WO2000069891A9 (en) 2002-07-04
AU5013600A (en) 2000-12-05
JP2003501012A (ja) 2003-01-14
EP1179010A2 (de) 2002-02-13
IL146459A0 (en) 2002-07-25
WO2000069891A3 (en) 2001-07-19
ATE365173T1 (de) 2007-07-15

Similar Documents

Publication Publication Date Title
DE60035270D1 (de) Previns als spezifische inhibitoren und therapeutika für botulinumtoxin b und tetanusneurotoxine
AR036196A1 (es) Agentes de contraste multimericos dirigidos a base de peptidos
DE69434817D1 (de) Protease varianten
DK1653989T3 (da) Antibakteriel sammensætning især mod gramnegative bakterier og som omfatter et peptid og et fortrinsvist hydrofobt antibakterielt middel
DE69033699T2 (de) Gegenüber eigenen inhibitoren resistente t-pa mutanten
NZ520659A (en) Xylanase variants having altered sensitivity to xylanase inhibitors caused by mutations in the lid region
ATE168130T1 (de) Stabilisierte enzyme und waschmittelzusammensetzungen
DE69717474T2 (de) Durch cyclische aminosäuren oder cyclische hydroxysäuren substituierte benzamidinderivate und deren verwendung als antikoagulantien
EE200100487A (et) Uudsed ühendid ja kompositsioonid proteaasiinhibiitoritena
NO930517L (no) Benzimidazolylderivater, legemidler inneholdende disse, og fremgangsmaate for deres fremstilling
DE60009511D1 (de) Nematizide trifluorbutene
NO302474B1 (no) Sakarinderivater, farmasöytisk sammensetning og anvendelse derav
NO20005261L (no) Nye heterocyklisk substituerte amider med cystein-protease- inhiberende virkning
ATE458057T1 (de) Varianten der faktor-vii- oder -viia-gla-domäne
SE9602263D0 (sv) New amino acid derivatives
DE69728869D1 (de) Von aminosauren und hydroxysauren substituierte benzamidinderivate und deren verwendung als antikoagulantien
ATE382604T1 (de) Aminosäure-derivate als hiv aspartyl-protease- inhibitoren
DE60221508D1 (de) Aminosäurederivate als hiv-protease-inhibitoren
PT830130E (pt) Enzima de conversao de tnf-alfa
BR9911891A (pt) Proteases fundidas com variantes de inibidor de subtilisina de streptomyces
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
LV10108A (lv) Sunu proliferacijas inhibitori farmaceitiska kompozicija savienojumu iegusanas metode sunu proliferacijas inhibesanas panemieni
WO2000069895A3 (en) Bufornin 1 as a specific inhibitor and therapeutic agent for botulinum toxin b and tetanus neurotoxins
RS50831B (sr) Izolovano antitelo ili fragment antitela koji se specifično vezuju za rg1 polipeptid
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition

Legal Events

Date Code Title Description
8332 No legal effect for de